The adjuvanted recombinant nanoparticle-based vaccine GBP510/AS03 shows a clinically acceptable safety profile and immunogenicity results comparable to that of the currently available ChAdOx1-S ...
The interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) have been updated to reflect latest ...
In a recent study posted to the medRxiv* pre-print server, researchers evaluated the immunogenicity of booster doses of alum-adjuvanted SCB-2019 vaccine candidate's three formulations. They tested ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results